Clinical Trial Update: Post-approval Study of NovoTTF-100A in Recurrent GBM Patients [Phase 4]

View source ↗

Summary

A post-approval Phase 4 study of NovoTTF-100A in patients with recurrent glioblastoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• NovoTTF-100A (Tumor Treating Fields therapy)

Snippet

Sponsor: NovoCure Ltd. | Conditions: Recurrent Glioblastoma Multiforme | Phase 4 | Status: TERMINATED